MyoKardia names new CEO
This article was originally published in Scrip
San Francisco-based MyoKardia, which develops therapeutics to treat genetic heart disease, has named Tassos Gianakakos chief executive office. Prior to joining MyoKardia Mr Gianakakos was senior vice-president and chief business officer at MAP Pharmaceuticals (acquired by Allergan in March 2013). Mr Gianakakos succeeds founding CEO Dr Charles Homcy who will remain on MyoKardia's board of directors.